Key Performance
More- Earnings Score: 2
- Momentum Score: 91
- True Yield: N/A
- Financial Health Score: 0
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Opus Genetics announced a virtual R&D Science Forum scheduled for June 16, 2026, featuring leading ophthalmology experts to discuss the company's gene therapy pipeline for inherited retinal diseases. The forum will highlight three programs entering clinical testing targeting RDH12, MERTK, and RHO mutations, along with updates on ongoing LCA5 and BEST1 clinical programs and market opportunities in the IRD space.
06/02/2026, 7:00 AM • GlobeNewswire
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced it will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company is advancing seven AAV-based programs, with lead candidates OPGx-LCA5 and OPGx-BEST1 targeting different retinal disorders.
05/27/2026, 8:00 AM • GlobeNewswire
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. The company is advancing its pipeline of seven AAV-based programs, with lead candidates OPGx-LCA5 and OPGx-BEST1.
05/13/2026, 7:00 AM • GlobeNewswire
The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.
05/11/2026, 1:00 PM • GlobeNewswire
Opus Genetics will present three abstracts at the ASCRS Annual Meeting in April 2026, including full results from Phase 3 studies evaluating phentolamine ophthalmic solution for presbyopia and mesopic vision disturbances. The company's partner Viatris is sponsoring an educational symposium on presbyopia management. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and advancing phentolamine as a small-molecule therapy.
04/10/2026, 6:59 AM • GlobeNewswire
Opus Genetics secured up to $155 million in non-dilutive funding from Oberland Capital Management, including an upfront $35 million and $5 million equity investment. The financing extends the company's cash runway into 2029 and will accelerate clinical development of gene therapy programs for inherited retinal diseases, with three additional programs expected to enter clinical testing over the next year. Three-month topline results from OPGx-BEST1 Phase 1/2 trial remain on track for mid-2026.
04/06/2026, 7:00 AM • GlobeNewswire
Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, has been recognized by Fast Company as one of the world's most innovative companies in the Biotech category for 2026. The company has advanced a pipeline of gene therapies including OPGx-BEST1 and OPGx-LCA5, employing a patient-centered approach to development.
03/24/2026, 7:00 AM • GlobeNewswire
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Opus Genetics announced its leadership team will participate in multiple leading ophthalmology and industry conferences in February 2026, including presentations on gene therapy advances and preliminary clinical results from its Phase 1b/2a study of OPGx-BEST1 for BEST1-related retinal degeneration. The company is advancing seven AAV-based gene therapy programs targeting inherited retinal diseases.
02/02/2026, 8:00 AM • GlobeNewswire
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Opus Genetics, a clinical-stage biopharmaceutical company, will present at the J.P. Morgan 2026 Healthcare Conference. The company focuses on developing gene therapies for inherited retinal diseases, with seven AAV-based programs targeting various genetic mutations.
12/11/2025, 7:00 AM • GlobeNewswire
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
Opus Genetics will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference, highlighting their gene therapies for inherited retinal diseases and ongoing clinical trials for treatments like OPGx-LCA5 and OPGx-BEST1.
10/14/2025, 8:00 AM • GlobeNewswire
Opus Genetics reported promising results from a Phase 1/2 clinical trial of OPGx-LCA5, a gene therapy for Leber Congenital Amaurosis type 5, showing significant vision improvements in pediatric and adult participants with no serious adverse events.
09/30/2025, 7:00 AM • GlobeNewswire
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics granted equity awards to its new Chief Financial Officer Rob Gagnon and five non-executive employees, including stock options and restricted stock units under the company's 2021 Inducement Plan.
09/12/2025, 8:00 AM • GlobeNewswire
